Barclays PLC Lexicon Pharmaceuticals, Inc. Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 146,071 shares of LXRX stock, worth $102,249. This represents 0.0% of its overall portfolio holdings.

Number of Shares

146,071

Previous 243,316 39.97%

Holding current value

$102,249

Previous $180,000 62.78%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.29 - $0.96 $28,201 - $93,355	-97,245 Reduced 39.97%	146,071 $67,000
Q4 2024 Feb 13, 2025	BUY	$0.65 - $2.08 $32,137 - $102,841	49,443 Added 25.5%	243,316 $180,000
Q3 2024 Nov 15, 2024	BUY	$1.51 - $2.39 $233,198 - $369,102	154,436 Added 391.6%	193,873 $304,000
Q2 2024 Aug 14, 2024	SELL	$1.54 - $2.28 $38,780 - $57,414	-25,182 Reduced 38.97%	39,437 $66,000
Q1 2024 May 15, 2024	SELL	$1.3 - $3.58 $81,116 - $223,381	-62,397 Reduced 49.13%	64,619 $155,000
Q4 2023 Feb 15, 2024	BUY	$1.0 - $1.53 $87,827 - $134,375	87,827 Added 224.11%	127,016 $195,000
Q3 2023 Nov 07, 2023	BUY	$1.06 - $2.33 $1,611 - $3,541	1,520 Added 4.04%	39,189 $42,000
Q2 2023 Aug 03, 2023	SELL	$2.15 - $3.49 $9,948 - $16,148	-4,627 Reduced 10.94%	37,669 $86,000
Q1 2023 May 04, 2023	BUY	$1.99 - $2.68 $39,672 - $53,428	19,936 Added 89.16%	42,296 $103,000
Q4 2022 Feb 13, 2023	BUY	$1.8 - $2.56 $33,892 - $48,202	18,829 Added 533.25%	22,360 $42,000
Q3 2022 Nov 03, 2022	SELL	$1.94 - $3.43 $139,142 - $246,009	-71,723 Reduced 95.31%	3,531 $8,000
Q2 2022 Aug 12, 2022	SELL	$1.31 - $2.69 $10,457 - $21,474	-7,983 Reduced 9.59%	75,254 $140,000
Q1 2022 May 16, 2022	SELL	$1.95 - $3.89 $3,379 - $6,741	-1,733 Reduced 2.04%	83,237 $175,000
Q4 2021 Feb 14, 2022	BUY	$3.81 - $6.16 $218,019 - $352,493	57,223 Added 206.23%	84,970 $335,000
Q3 2021 Nov 09, 2021	BUY	$3.38 - $5.35 $48,999 - $77,558	14,497 Added 109.41%	27,747 $134,000
Q2 2021 Aug 13, 2021	SELL	$4.12 - $5.87 $116,917 - $166,578	-28,378 Reduced 68.17%	13,250 $60,000
Q1 2021 May 13, 2021	BUY	$3.45 - $9.09 $97,455 - $256,774	28,248 Added 211.12%	41,628 $244,000
Q4 2020 Feb 11, 2021	SELL	$1.05 - $3.67 $6,067 - $21,208	-5,779 Reduced 30.16%	13,380 $46,000
Q3 2020 Nov 12, 2020	SELL	$1.44 - $2.1 $178,372 - $260,127	-123,870 Reduced 86.6%	19,159 $27,000
Q2 2020 Aug 12, 2020	BUY	$1.75 - $2.3 $126,962 - $166,865	72,550 Added 102.94%	143,029 $287,000
Q1 2020 May 13, 2020	BUY	$1.8 - $4.28 $22,275 - $52,965	12,375 Added 21.3%	70,479 $138,000
Q4 2019 Feb 10, 2020	BUY	$3.16 - $5.15 $104,596 - $170,465	33,100 Added 132.38%	58,104 $241,000
Q3 2019 Nov 14, 2019	SELL	$1.2 - $6.66 $2,460 - $13,653	-2,050 Reduced 7.58%	25,004 $75,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $58,550 - $77,811	10,944 Added 67.93%	27,054 $170,000
Q1 2019 May 15, 2019	BUY	$4.36 - $7.94 $58,873 - $107,213	13,503 Added 517.95%	16,110 $89,000
Q4 2018 Feb 14, 2019	SELL	$6.15 - $10.51 $123,258 - $210,641	-20,042 Reduced 88.49%	2,607 $18,000
Q3 2018 Nov 14, 2018	BUY	$10.32 - $13.06 $201,085 - $254,474	19,485 Added 615.83%	22,649 $241,000
Q2 2018 Aug 14, 2018	SELL	$7.8 - $13.69 $123,240 - $216,302	-15,800 Reduced 83.32%	3,164 $38,000
Q1 2018 May 15, 2018	SELL	$7.86 - $11.39 $308,748 - $447,410	-39,281 Reduced 67.44%	18,964 $163,000
Q4 2017 Feb 14, 2018	BUY	$8.77 - $12.28 $174,294 - $244,052	19,874 Added 51.79%	58,245 $575,000
Q3 2017 Nov 14, 2017	BUY	$12.17 - $16.3 $466,975 - $625,447	38,371	38,371 $471,000

Others Institutions Holding LXRX

# of Institutions

134

Shares Held

196M

Call Options Held

310K

Put Options Held

77.3K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $132M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account